{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Overall Survival at 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Overal Survival at 2 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Overall Survival at 3 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The proportion of study participants alive at 1, 2 and 3 years","groups":[{"description":"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nnilotinib: Given PO\n\nimatinib mesylate: Given PO\n\npharmacological study: Correlative studies","id":"OG000","title":"Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Overall Survival (complete follow-up is available out to three years for all patients)","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Survival","type":"SECONDARY","unitOfMeasure":"Participants"}